Dr. Frédérique Vegran – immuno oncology –  Best Researcher Award

Dr. Frédérique Vegran - immuno oncology -  Best Researcher Award

INSERM - France

Author Profile 

GOOGLE SCHOLAR 

🎓 Early academic pursuits

Frédérique Vegran began her scientific journey with a strong foundation in cellular and molecular biology, earning her phd in this domain. during her early academic years, she exhibited a keen interest in understanding cellular behavior under varying physiological conditions. this led her to pursue advanced studies and training in belgium, where she spent three years as a post-doctoral researcher. her research during this time revolved around the tumor microenvironment, hypoxia, and metabolic regulation—areas that laid the groundwork for her future focus in immuno-oncology, a field now evolving alongside advancements in power electronics and biotechnology integration.

🧪 Professional endeavors

Currently a full-time research scientist at inserm umr1231 in dijon, france, frédérique vegran has established herself as a leading figure in immuno-oncology. her professional tenure is marked by active involvement in cutting-edge research aimed at enhancing anti-tumor immune responses. she has supervised multiple phd candidates and participated in thesis evaluation committees, highlighting her commitment to nurturing future generations of scientists. her involvement in research also bridges academic curiosity with translational potential—something akin to the precision and adaptability found in modern power electronics systems.

🔬 Contributions and research focus

Vegran’s groundbreaking contributions have significantly advanced our understanding of t cell biology in cancer. one of her landmark findings includes the role of il-1b in promoting the anti-tumor effect of th9 cells (nature immunology, 2013). she also revealed a novel transcriptional function of nlrp3 in th2 cells (nature immunology, 2015), and more recently, identified the immuno oncology regulatory role of nlrp3 in th17 differentiation and its acquisition of treg-like properties within tumor environments (cellular and molecular immunology, 2025). such insights have reinforced the importance of targeted immune modulation—an idea resonating with the fine-tuning concepts used in power electronics.

🌍 Impact and influence

Her influence extends beyond publications, with an h-index of 37 and i10 index of 52, demonstrating consistent citation and global recognition of her work. having authored over 67 peer- immuno oncology reviewed articles, including in top-tier journals, frédérique vegran continues to impact the scientific discourse in immuno-oncology. her discoveries have paved new avenues for therapeutic strategies, inspiring researchers globally to explore the interplay between immune cells and cancer. her professional memberships with the french society of immunology (sfi) and the french society for immunotherapy of cancer (fitc) further signify her standing in the field.

📊 Academic cites

Vegran’s academic output is notable with 67 journal publications indexed in scopus and sci, alongside 8 completed and 3 ongoing research projects. she has contributed to 3 immuno oncology consultancy/industry-related projects and has 2 patents published, highlighting her dual focus on innovation and application. although she has not authored books, her work stands as a valuable reference across the immunological and oncological academic landscapes.

🧬 Legacy and future contributions

Frédérique Vegran’s legacy lies in the transformative nature of her research on immune modulation in cancer. her consistent engagement in phd mentorship, cutting-edge experimentation, and scientific evaluation sets a strong example for academic leadership. looking ahead, her research is poised to further decode immune-cancer interactions, potentially contributing to the development of novel therapeutic interventions that integrate cellular biology with advanced technologies, much like how power electronics revolutionized modern engineering systems.

Notable Publications 

  1. Title: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
    Authors: P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, ...
    Journal: The Journal of Clinical Investigation

  2. Title: Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis
    Authors: F. Végran, R. Boidot, C. Michiels, P. Sonveaux, O. Feron
    Journal: Cancer Research

  3. Title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
    Authors: M. Bruchard, G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, ...
    Journal: Nature Medicine

  4. Title: Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis
    Authors: P. Sonveaux, T. Copetti, C.J. De Saedeleer, F. Vegran, J. Verrax, ...
    Journal: PLOS ONE

  5. Title: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
    Authors: M. Bruchard, C. Rebé, V. Derangère, D. Togbé, B. Ryffel, R. Boidot, ...
    Journal: Nature Immunolog

Dr. Nazia Chaudhary -Cancer research- therapy resistance – Best Researcher Award 

ACTREC,TMC - India

Author Profile 

ORCID

🧪 Early academic pursuits

Chaudhary s. nazia's academic journey began with an intense passion for microbiology, which led her to achieve a stellar 80% in her bachelor’s degree from sophia college, university of mumbai, in 2013. she further pursued a master’s degree in microbiology at st. xavier’s college, where she graduated with distinction, securing 73.5% in 2015. her academic foundation set the stage for a doctoral pursuit at the advanced centre for treatment, research, and education in cancer (actrec), where she completed her phd in march 2022. her research explored the intricate mechanisms that promote tumorigenesis and resistance to radio- and chemotherapy.

🧬 Professional endeavors

Nazia embarked on a remarkable career as a dst inspire faculty at actrec-tata memorial centre (tmc). her dedication to understanding cancer biology has been a cornerstone of her professional work. through rigorous experimentation and innovative approaches, she has consistently contributed to advancing research in oncology. her faculty position at actrec underscores her commitment to fostering new scientific breakthroughs and mentoring future researchers in the field.

🔬 Contributions and research focus

Nazia’s research revolves around understanding cancer mechanisms at the molecular level. her phd project provided groundbreaking insights into the pathways that promote tumorigenesis and resistance to treatment in the absence of plakophilin 3. her earlier work includes projects on thermophiles from ganeshpuri hot springs, Cancer research- therapy resistance mitochondrial function regulation, and industrially important thermophilic actinomycetes. her innovative studies highlight her ability to blend fundamental microbiological concepts with cutting-edge biomedical applications.

🏆 Accolades and recognition

Nazia’s groundbreaking research has been recognized through prestigious patents. she is a co-inventor of two patents focused on antibodies against lipocalin-2 and Cancer research- therapy resistance their therapeutic applications. these patents signify her impactful contributions to cancer treatment strategies and her recognition as a key innovator in her field.

🌍 Impact and influence

Nazia’s work has influenced the scientific community by providing deeper insights into tumor biology and therapeutic resistance. her contributions to understanding Cancer research- therapy resistance mitochondrial regulation and cancer pathways have added valuable knowledge to the field of molecular oncology. as a dst inspire faculty, she continues to inspire and guide young researchers, amplifying her influence in shaping the next generation of scientists.

🌟 Legacy and future contributions

With her focus on uncovering novel therapeutic targets and mechanisms in oncology, nazia aims to create a legacy of impactful research that bridges fundamental science and clinical applications. her continued efforts in cancer research promise to deliver innovative solutions that could transform patient care and improve outcomes for those affected by the disease. her dedication to mentorship ensures her knowledge and passion will resonate through the researchers she inspires.

Notable Publications 

  • Title: LCN2 promotes focal adhesion formation and invasion by stimulating Src activation
    Author(s): Bhagya Shree Choudhary; Nazia Chaudhary; Aditi Vijan; Dibita Mandal; Leena Pilankar; Shubham Gawand; Bushra K. Khan; Anusha Shivashankar; Rinki Doloi; Neha Joshi et al.
    Journal: Preprint
  • Title: EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
    Author(s): Nazia Chaudhary; Bhagya Shree Choudhary; Anusha Shivashankar; Subhakankha Manna; Khyati Ved; Shagufa Shaikh; Sonal Khanna; Jeetnet Barr; Jagruti Dani; Nandini Verma
    Journal: Preprint
  • Title: GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibition
    Author(s): Nazia Chaudhary; Bhagya Shree Choudhary; Sushmita Patra; Shivani Malvankar; Anusha Shivashankar; Eeshrita Jog; Vaishali V. Kailje; Sonal Khanna; Subhakankha Manna; Sarthak Sahoo et al.
    Journal: Preprint
  • Title: Lipocalin 2 inhibits actin glutathionylation to promote invasion and migration
    Author(s): Choudhary BS; Chaudhary N; Shah M; Dwivedi N; P K S; Das M; Dalal SN
    Journal: FEBS Letters
  • Title: The Role of Lipocalin 2 (LCN2) in Regulating Ferroptosis and Therapy Resistance
    Author(s): Rinki Doloi; Nazia Chaudhary; Sorab N. Dalal
    Journal: National Research Scholars' Meet 2021 - Abstracts

Dr. Hui Jia – Tumor chemotherapy resistance – Best Researcher Award

Dr. Hui Jia - Tumor chemotherapy resistance - Best Researcher Award

Shenyang Medical College - China 

Author Profile 

SCOPUS 

Early academic pursuits 📚

Dr. Hui Jia's journey in traditional chinese medicine began with a solid academic foundation. she earned her bachelor of pharmacy from shenyang pharmaceutical university, which sparked her interest in natural medicine and pharmacology. pursuing further studies, she obtained a master’s degree in traditional chinese medicine from shaanxi university of traditional chinese medicine. in 2021, she completed her ph.d. in traditional chinese medicine from shenyang pharmaceutical university, where her research honed in on the bioactive compounds of medicinal herbs and their therapeutic potential.

Professional endeavors 🏛️

Dr. Jia is currently an associate professor at the school of traditional chinese medicine, shenyang medical college. she has played a key role in shaping the institution’s research focus on herbal medicines and natural products. her dedication to teaching and mentorship is evident, as she actively guides students in exploring the intricate mechanisms of traditional remedies, while leading significant research projects that address major health challenges like drug-resistant cancers.

Contributions and research focus 🔬

Dr. Hui jia’s primary research revolves around understanding the active ingredients of herbs and their molecular mechanisms, particularly in reversing drug Tumor chemotherapy resistance resistance. her work is centered on investigating the key protein targets of natural products. one of her significant contributions is her research on cimigenoside, a bioactive compound from cohosh, and its role in combating drug resistance in triple-negative breast cancer through the γ-secretase/nicd/notch-pxr axis. her innovative approach offers new insights into cancer treatment.

Accolades and recognition 🏅

Through her groundbreaking research, dr. jia has gained recognition in the scientific community. she has secured prestigious grants from both the national natural science foundation of china and liaoning province for her work on cancer drug resistance. her research projects reflect her excellence and leadership in the field of Tumor chemotherapy resistance traditional chinese medicine, addressing complex challenges in cancer treatment and advancing the potential of natural products as therapeutic agents.

Impact and influence 🌍

Dr. jia's research has far-reaching implications, particularly in the realm of cancer therapeutics. her work on γ-secretase inhibitors and their role in reversing drug resistance in triple-negative breast cancer highlights the importance of integrating traditional medicine with modern science. her studies provide new avenues for Tumor chemotherapy resistance treating difficult cancers, potentially transforming how drug resistance is managed in clinical settings.

Legacy and future contributions 🔮

with her deep-rooted passion for traditional chinese medicine, dr. hui jia is set to leave a lasting legacy in the field. her future contributions are expected to further bridge the gap between traditional herbal medicine and contemporary drug discovery. as she continues to explore the bioactive compounds of natural products and their mechanisms of action, her work will undoubtedly influence future generations of researchers and contribute to innovative cancer therapies.

Notable Publications 

  1. Atorvastatin ameliorates diabetic nephropathy through inhibiting oxidative stress and ferroptosis signaling
    Authors: Zhang, Y., Qu, Y., Cai, R., Ren, F., Zhou, M.-S.
    Journal: European Journal of Pharmacology, 2024, 976, 176699
  2. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance
    Authors: Feng, M., Santhanam, R.K., Xing, H., Zhou, M., Jia, H.
    Journal: Biochemical Pharmacology, 2024, 220, 115991
  3. The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling
    Authors: Xu, Q., Zhuo, K., Zhang, X., Dong, J., Zhou, M.-S.
    Journal: European Journal of Pharmacology, 2024, 962, 176252
  4. Cardiac macrophages in maintaining heart homeostasis and regulating ventricular remodeling of heart diseases
    Authors: Kang, M., Jia, H., Feng, M., Zhang, L., Zhou, M.-S.
    Journal: Frontiers in Immunology, 2024, 15, 1467089
  5. Cigarette smoke-induced exosomal miR-221-3p facilitates M1 macrophage polarization via the STAT3 pathway in chronic obstructive pulmonary disease
    Authors: Jia, H., He, W., Wu, B., Wang, M., Xia, S.
    Journal: Aging, 2024, 16(17), pp. 12379–12391

Prof Dr. Zhen Yang – Oncology and immunity – Young Scientist Award

Prof Dr. Zhen Yang - Oncology and immunity - Young Scientist Award

Tianjin Union Medical Center of Nankai University - China

Author Profile 

ORCID

Early academic pursuits 🎓

Dr. Zhen Yang embarked on a journey in the medical field with a focus on understanding complex biological systems. With a Doctor of Medicine degree, Zhen cultivated a deep interest in the mechanisms of diseases, particularly malignant tumors. This foundation laid the groundwork for a career dedicated to advancing medical science and improving therapeutic strategies.

Professional endeavors 🏢

Currently, Zhen serves as a postdoctoral research fellow and a distinguished research fellow, overseeing laboratory technicians and guiding research initiatives. Zhen has played a crucial role in leading significant projects, including the National Natural Science Foundation of China and key initiatives from the Tianjin Health and Education Commissions. These positions reflect Zhen's leadership and commitment to fostering innovative research environments.

Contributions and research focus 🔬

Zhen's research primarily centers on immunotherapy for malignant tumors, integrating Chinese and Western medicine approaches. This unique perspective aims to enhance treatment efficacy and patient outcomes. With over ten published papers in prestigious journals, including Oncology and immunity Autophagy, Cancer Letters, and International Journal of Biological Macromolecules, Zhen's work significantly contributes to the scientific understanding of immunotherapeutic strategies and their applications in clinical settings.

Accolades and recognition 🏅

Zhen's contributions to medical research have not gone unnoticed, with recognition from various academic bodies and funding agencies. Leading projects funded by the National Natural Science Foundation of China and receiving support from Tianjin’s health and education sectors Oncology and immunity underscores Zhen's influence and reputation within the scientific community. Zhen’s work has been pivotal in advancing research methodologies and clinical applications in immunotherapy.

Impact and influence 🌍

The impact of Zhen Yang's research extends beyond academic publications, influencing clinical practices and therapeutic strategies for treating malignant tumors. By bridging traditional and modern medicine, Zhen's work fosters a holistic approach to cancer treatment, potentially Oncology and immunity transforming how therapies are designed and implemented. Zhen’s research serves as a valuable resource for other scientists and clinicians in the field.

Legacy and future contributions 🔮

Dr. Zhen Yang's legacy is one of innovation and dedication to improving cancer therapies. As research in immunotherapy continues to evolve, Zhen is poised to make further significant contributions that could redefine treatment paradigms. The integration of traditional and modern practices in Zhen's work promises to open new avenues for research and clinical application, ensuring a lasting impact on future generations of medical professionals and researchers.

Notable Publications